About Aiforia
Aiforia is a company based in Helsinki (Finland) founded in 2014.. Aiforia has raised $22.99 million across 7 funding rounds from investors including European Union, Business Finland and Epredia. The company has 3 employees as of December 31, 2022. Aiforia offers products and services including Aiforia® Breast Cancer Suite, Aiforia® Lung Cancer Suite, Aiforia® Prostate Cancer Suite, Aiforia® Colon Suite, and Aiforia® Gastric Suite. Aiforia operates in a competitive market with competitors including Viz.ai, PathAI, Deepcell, Aignostics and Deciphex, among others.
- Headquarter Helsinki, Finland
- Employees 3 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aiforia Technologies Oy Class A
-
Annual Revenue
$2.96 M (USD)18.93as on Dec 31, 2024
-
Net Profit
$-12.41 M (USD)7.57as on Dec 31, 2024
-
EBITDA
$-12.62 M (USD)3.53as on Dec 31, 2024
-
Total Equity Funding
$22.99 M (USD)
in 7 rounds
-
Latest Funding Round
$4.92 M (USD), Post-IPO
Dec 12, 2025
-
Investors
European Union
& 7 more
-
Employee Count
3
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aiforia
Aiforia is a publicly listed company on the OMXHEX with ticker symbol AIFORIA in Finland, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aiforia
Aiforia offers a comprehensive portfolio of products and services, including Aiforia® Breast Cancer Suite, Aiforia® Lung Cancer Suite, Aiforia® Prostate Cancer Suite, Aiforia® Colon Suite, and Aiforia® Gastric Suite. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI for analyzing breast cancer images in diagnostics.
AI for lung cancer image screening and analysis.
AI platform for prostate cancer diagnostics and reporting.
AI for colon cancer image analysis in clinical settings.
AI tools for gastric cancer diagnostics and visualization.
Tool for creating custom AI models in pathology research.
Unlock access to complete
Unlock access to complete
Funding Insights of Aiforia
Aiforia has successfully raised a total of $22.99M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.92 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $4.9M
-
First Round
First Round
(21 Oct 2015)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Post-IPO - Aiforia | Valuation |
investors |
|
| Jun, 2021 | Amount | Series B - Aiforia | Valuation | Epredia |
|
| Feb, 2021 | Amount | Grant - Aiforia | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aiforia
Aiforia has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include European Union, Business Finland and Epredia. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is invested in early-stage disruptors for global ventures.
|
Founded Year | Domain | Location | |
|
Early-stage investments are directed toward disruptive technologies and innovations.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aiforia
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aiforia
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aiforia Comparisons
Competitors of Aiforia
Aiforia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viz.ai, PathAI, Deepcell, Aignostics and Deciphex, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI and cloud-powered software for stroke care coordination is developed.
|
|
| domain | founded_year | HQ Location |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| domain | founded_year | HQ Location |
AI-powered single cell classification and isolation technology for clinical research
|
|
| domain | founded_year | HQ Location |
AI-based pathology diagnostic software is provided for medical analysis.
|
|
| domain | founded_year | HQ Location |
Digital pathology software is developed for clinical and veterinary productivity.
|
|
| domain | founded_year | HQ Location |
Provides image analysis and data mining solutions for quantitative digital pathology in the healthcare industry
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aiforia
Frequently Asked Questions about Aiforia
When was Aiforia founded?
Aiforia was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Aiforia located?
Aiforia is headquartered in Helsinki, Finland.
Is Aiforia a funded company?
Aiforia is a funded company, having raised a total of $22.99M across 7 funding rounds to date. The company's 1st funding round was a Grant of $483.61K, raised on Oct 21, 2015.
How many employees does Aiforia have?
As of Dec 31, 2022, the latest employee count at Aiforia is 3.
What is the annual revenue of Aiforia?
Annual revenue of Aiforia is $2.96M as on Dec 31, 2024.
What does Aiforia do?
Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas. It provides analysis of digital pathology images for pathologists and researchers. The products are aiforia create, aiforia on-demand, and aiforia cloud.
Who are the top competitors of Aiforia?
Aiforia's top competitors include Aignostics, Deciphex and Pictor Labs.
What products or services does Aiforia offer?
Aiforia offers Aiforia® Breast Cancer Suite, Aiforia® Lung Cancer Suite, Aiforia® Prostate Cancer Suite, Aiforia® Colon Suite, and 2 more products and services.
Is Aiforia publicly traded?
Yes, Aiforia is publicly traded on OMXHEX under the ticker symbol AIFORIA.
Who are Aiforia's investors?
Aiforia has 8 investors. Key investors include European Union, Business Finland, Epredia, Ascend Capital Partners, and ACME Capital.
What is Aiforia's ticker symbol?
The ticker symbol of Aiforia is AIFORIA on OMXHEX.